TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26099553
Drug: Low-dose Huo-Luo-Xiao-Ling
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Huo-Luo-Xiao-Ling (HLXL)-Dan (2400 mg/day) for 6 weeks
Study: 26099553
Drug: High-dose Huo-Luo-Xiao-Ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Huo-Luo-Xiao-Ling (HLXL)-Dan (4000 mg/day for week 1-2, and 5600 mg/day for week 3-8) for 8 weeks
Study: 15062145
Drug: HDR (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDR (high-dose rate) intracavitary brachytherapy
Study: 15062145
Drug: MDR (medium-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDR (medium-dose rate) intracavitary brachytherapy
Study: 10920215
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral calcitriol (0.5 microg/day) combined with nasal salmon calcitonin (200 U/day) for the first 3 months (group A)
Study: 10920215
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous pamidronate (0.5 mg/kg body weight) every third month (group B)
Study: 10920215
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (calcitriol with calcitonin and pamidronate)
Study: 3877287
Drug: Control (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (all other drugs)
Study: 30532155
Drug: Narrative Community‐Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Community‐Based Group Therapy
Study: 15571828
Drug: abciximab (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: abciximab (0.25 mg/kg bolus followed by 10 microg/min infusion) during the organization phase for pPCI (Group 1, n=28)
Study: 15571828
Drug: abciximab (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: abciximab (0.25 mg/kg bolus followed by 10 microg/min infusion) immediately before pPCI (Group 2, n=27)
Study: 27353271
Drug: Velpatasvir (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velpatasvir (150 mg)
Study: 25090617
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (nitrendipine 10-40 mg/day, possibly with enalapril 5-20 mg/day and/or hydrochlorothiazide 12.5-25.0 mg/day)
Study: 20368235
Drug: intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intensive medical therapy alone
Study: 20368235
Drug: insulin sensitization
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: insulin sensitization therapy
Study: 20368235
Drug: insulin provision
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: insulin provision therapy
Study: 10719944
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 800 microg (three consecutive doses)
Study: 10719944
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 15 microg/kg
Study: 30408272
Drug: Lip trill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lip trill therapy
Study: 30408272
Drug: Straw phonation
Normalized name: oat straw extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Straw phonation therapy
Study: 30408272
Drug: Water-resistance therapy
Normalized name: copper naphthenate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-resistance therapy (WRT)
Study: 25813205
Drug: Palbociclib 100
Normalized name: palbociclib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib 100 mg orally once daily on days 1-12 of a 21-day cycle with bortezomib 1.0 mg/m2 (IV) and dexamethasone 20 mg (orally 30 min pre-bortezomib dosing) on days 8 and 11 and days 15 and 18
Study: 23045618
Drug: Multiple-dose DAS181
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose DAS181
Study: 18577791
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy for 12 weeks
Study: 16172952
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus rituximab (MCP+R)
Study: 16172952
Drug: Chemotherapy (MCP)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (MCP)
Study: 16172952
Drug: Mantle cell
Normalized name: garden lady's mantle extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mantle cell lymphoma treatment
Study: 10432137
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of PGE2 (Prepidil) administered intracervically at 39 weeks' gestation, repeated weekly for up to three doses.
Study: 10432137
Drug: Expectant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectant treatment (control group).
Study: 2111220
Drug: Glucose-electrolyte solution
Normalized name: glucose Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-electrolyte solution labeled with stable isotope H2O18
Study: 20678233
Drug: Telephone-delivered behavioural
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered behavioural weight loss intervention focusing on physical activity, diet, and behavioural therapy (18 months duration, with a 6-month intensive phase and a 12-month maintenance phase).
Study: 17656445
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion (3 kcal/min for 60 min)
Study: 16783811
Drug: Quetiapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (mean dose 637 mg/day, mean treatment duration 80 days)
Study: 16783811
Drug: Olanzapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (mean dose 16 mg/day, mean treatment duration 78 days)
Study: 10783609
Drug: Individual outcome-oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual outcome-oriented cardiologic rehabilitation treatment
Study: 8627110
Drug: Mixed antileprosy
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed antileprosy vaccine containing killed Mycobacterium leprae of human origin plus M. bovis BCG
Study: 8627110
Drug: Multidrug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug therapy (MDT) only
Study: 3918196
Drug: 15% glucose‐3.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% glucose‐3.3% Intralipid‐5% amino acid solution (group G‐F)
Study: 3918196
Drug: 25% glucose‐5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% glucose‐5% amino acid solution (group G)
Study: 3918196
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (group G and group G‐F)
Study: 31706658
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula oxygen (HFNC) at a flow of 60 L/min
Study: 31706658
Drug: Conventional reserve-bag
Normalized name: obecabtagene autoleucel
DrugBank: Obecabtagene autoleucel (DB17362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional reserve-bag oxygen therapy (NBO2) at a flow of 15 L/min
Study: 31706658
Drug: Conventional reserve-bag
Normalized name: obecabtagene autoleucel
DrugBank: Obecabtagene autoleucel (DB17362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional reserve-bag oxygen therapy (NBO2)
Study: 10972687
Drug: Prednisolone 60
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 60 mg/m2 daily for six weeks, followed by 40 mg/m2 on alternate days for six weeks
Study: 10972687
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg/m2 daily for six weeks
Study: 1473873
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride in polyethylene glycol (MHP) suppository
Study: 1473873
Drug: Morphine alkaloid
Normalized name: opium alkaloids with morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine alkaloid in Novata BBC (MAN) suppository
Study: 6202753
Drug: Ketoconazole, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole, 400 mg once daily (K)
Study: 6202753
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B tablets and lozenges (A)
Study: 29687877
Drug: Adenosine combined
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine combined with micro-pump intravenous infusion of tirofiban
Study: 22008899
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (topiramate plus nortriptyline)
Study: 22008899
Drug: Monotherapy (placebo)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (placebo)
Study: 17337492
Drug: Ramipril 5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5/10 mg
Study: 15114377
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 1.250 mg twice daily (500 mg Ca2+ per tablet)
Study: 15114377
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 1.250 mg twice daily plus 400 IU vitamin D3 b.i.d.
Study: 9421346
Drug: Psychoeducational medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational medication management training (PMT) + cognitive psychotherapy (CP) + key‐person counselling (KC)
Study: 8318411
Drug: Continuous chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous chemotherapy in biochemically defined responders
Study: 8318411
Drug: Maintenance hormones
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintenance hormones after 6 months
Study: 8318411
Drug: Continue chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue chemotherapy while biochemical markers kept falling or remained normal
Study: 3011917
Drug: Intranasal recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal recombinant alpha interferon (IFN‐alpha 2b) 1,500,000 IU twice daily
Study: 3011917
Drug: Intranasal recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal recombinant alpha interferon (IFN‐alpha 2b)
Study: 3011917
Drug: Intranasal recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal recombinant alpha interferon (IFN‐alpha 2b) or placebo once daily
Study: 30776365
Drug: Antibiotic management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic management based on rapid diagnostic testing (RDT)
Study: 30776365
Drug: Antibiotic management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic management based on RDT
Study: 26715485
Drug: 40 IU
Normalized name: Oxytocin 40 IU/1 ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU of intranasal OXT
Study: 17884346
Drug: Botanical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botanical formulation (rose hips, blueberry and blackberry mixture, grapevine extract)
Study: 17884346
Drug: Botanical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botanical formulation
Study: 12126522
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1.0 g/d (body weight < 50 kg) or 1.5 g/d (body weight > 50 kg), reduced to 0.75-1.0 g/d after 6 months, maintaining dosage of 0.5-0.75 g/d after 12 months, total treatment duration at least 12 months.
Study: 12126522
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received prednisone orally at 0.8 mg/kg/d.
Study: 10530284
Drug: Active vertical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active vertical corrector (AVC) treatment followed by fixed 022 orthodontic appliances
Study: 7548920
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g lactulose
Study: 7548920
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g inulin
Study: 7548920
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g inulin
Study: 7548920
Drug: resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: resistant starch (6.1 g)
Study: 6783524
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition regimen consisting of 0.6 g amino acid and 4.0 g carbohydrate/kg BW/day
Study: 6783524
Drug: Isocaloric amounts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric amounts of carbohydrate (5.0 g/kg BW/day) alone
Study: 31161236
Drug: 14 baths
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 baths in thermal water for a month plus standard pharmacological treatment (Group A Phase 1)
Study: 31161236
Drug: Standard pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacological treatment (Group B Phase 1)
Study: 31161236
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Group A Phase 2)
Study: 31161236
Drug: 14 baths
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 baths in thermal water for a month plus standard treatment (Group B Phase 2)
Study: 26336909
Drug: 6-week intranasal
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week intranasal administration of oxytocin
Study: 21876564
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg A3309
Study: 17723083
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with amiodarone and sotalol
Study: 17723083
Drug: Sotalol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol monotherapy
Study: 17723083
Drug: Amiodarone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone monotherapy
Study: 8833170
Drug: Injective immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injective immunotherapy (SIT)
Study: 3830240
Drug: FCE20700 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCE20700 (1 mg, 2 mg)
Study: 3830240
Drug: FCE20700 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCE20700 (2 mg)
Study: 29722834
Drug: Caloric sweeteners
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caloric sweeteners (50 g glucose and 25 g fructose)
Study: 29722834
Drug: Noncaloric sweetener
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncaloric sweetener (220 mg acesulfame-K)
Study: 26494130
Drug: Panobinostat single-agent
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat single-agent trials
Study: 16895639
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) pretreatment with recombinant human FSH (r-hFSH) starting on day 2 or 3 after OC withdrawal.
Study: 1373779
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 to 80 mg per day) for 12 weeks
Study: 1373779
Drug: Finasteride (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (0.2 to 40 mg per day) for 24 weeks
Study: 1373779
Drug: Finasteride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (1 and 5 mg groups combined)
Study: 1373779
Drug: Finasteride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (1 and 5 mg groups)
Study: 4040050
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Reglan and Solu‐medrol
Study: 25317619
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate solution (3 ml/kg of sodium bicarbonate solution (150 mEq/L) one hour prior to procedure and then drip rate decreased to 1 ml/kg/hour until 6 hours post procedure)
Study: 25317619
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride solution (1 ml/kg/hour of normal saline solution, starting 12 hours before and continuing 12 hours after iohexol contrast)
Study: 19602993
Drug: Light protected
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light protected parenteral nutrition
Study: 19602993
Drug: Light exposed
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light exposed parenteral nutrition
Study: 19083385
Drug: Beta-alanine supplementation
Normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine supplementation (4.5 g x d(‐1))
Study: 19083385
Drug: Placebo (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4.5 g x d(‐1) of maltodextrin)
Study: 8720611
Drug: Anthropometric characteristics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthropometric characteristics, 2-h post-load specific insulin levels, fasting proinsulin/fasting insulin ratio
Study: 1359258
Drug: Enalapril (2.5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5‐20 mg per day)
Study: 3994881
Drug: Lower concentrations
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower concentrations of volatile agents
Study: 25122121
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 400 mg tribendimidine
Study: 25122121
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tribendimidine twice daily
Study: 25122121
Drug: 75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/kg praziquantel divided in four doses within 2 days
Study: 25122121
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 400 mg mebendazole
Study: 16438370
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Vaxigrip and Arbidol
Study: 25947165
Drug: Rabies vaccine
Normalized name: RABIES VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabies vaccine (control).
Study: 24078508
Drug: Doxazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (2 mg at night for two weeks, increasing to 4 mg for a further two weeks)
Study: 24078508
Drug: Intranasal desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal desmopressin (20 μg at night)
Study: 21491106
Drug: Oral Phe
Normalized name: Phe
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Phe load (100 mg/kg body weight) administered to PKU patients prior to one fMRI session (placebo-controlled)
Study: 21491106
Drug: Oral Phe
Normalized name: Phe
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Phe load (100 mg/kg body weight)
Study: 2655681
Drug: Frusemide 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 100 mg
Study: 2655681
Drug: Bumetanide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide 2.5 mg
Study: 319892
Drug: Primary additive
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary additive hormone therapy followed by adrenalectomy
Study: 319892
Drug: Primary adrenalectomy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary adrenalectomy followed by chemotherapy and/or additive hormone therapy
Study: 319892
Drug: Adrenalectomy-oophorectomy as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenalectomy-oophorectomy as primary mode of therapy
Study: 319892
Drug: Sequential hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential hormonal manipulation
Study: 28575496
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (r‐ESWT)
Study: 19618229
Drug: Functional dysphagia
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional dysphagia therapy with PEG feeding (group 1, n=59)
Study: 19618229
Drug: Functional dysphagia
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional dysphagia therapy without PEG feeding (group 2, n=105)
Study: 15219637
Drug: G331A polymorphism
Normalized name: ANGELICA POLYMORPHA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: G331A polymorphism in the progesterone receptor gene
Study: 15219637
Drug: PROGINS polymorphism
Normalized name: Angelica polymorpha root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROGINS polymorphism in the progesterone receptor gene
Study: 11588508
Drug: Didanosine enteric-coated
Normalized name: didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine enteric-coated capsules (Videx EC)
Study: 11588508
Drug: Didanosine tablets
Normalized name: didanosine Chewable Tablet
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine tablets
Study: 9332685
Drug: Alternating chemoradiotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemoradiotherapy with cisplatin (20 mg/m2/day) and fluorouracil (200 mg/m2/day) for five consecutive days (CF)
Study: 9332685
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy with vinblastine and bleomycin followed by standard radiotherapy (VBM)
Study: 9332685
Drug: Sequential VBM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential VBM and radiation